AIMC Topic: Sodium-Glucose Transporter 2

Clear Filters Showing 1 to 2 of 2 articles

Decoding empagliflozin's molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence.

Scientific reports Jun 8, 2021
The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear. Here we aimed to use artificial int...
Humans Artificial Intelligence Stroke Volume Myocardium Glucosides Heart Failure Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors Sodium-Glucose Transporter 2 Models, Cardiovascular Sodium-Hydrogen Exchanger 1
View on PubMed DOI

Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.

Reviews in cardiovascular medicine Jun 30, 2018
In this systematic review, we sought to summarize the 3 recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials (Dapagliflozin Effect on CardiovasculAR Events (DECLARE-TIMI 58), Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, ...
Humans Research Design Biomarkers Risk Factors Cardiovascular Diseases Comorbidity Blood Glucose Diabetes Mellitus, Type 2 Treatment Outcome Health Status Kidney Diseases Randomized Controlled Trials as Topic Cause of Death Glucosides Benzhydryl Compounds Canagliflozin Sodium-Glucose Transporter 2 Inhibitors Sodium-Glucose Transporter 2
View on PubMed DOI
Popular Topics
Recent Journals